Dr. Yogesh Shouche is appointed as Director of SKAN

Mr.
Dr. Yogesh Shouche, Director, SKAN, said "I am honoured to accept the responsibility given by SKAN and the faith reposed in me. I value this opportunity and would work towards making SKAN a world-class place for deep science with a strong focus on societal needs. With the SKAN team I will work to build and nurture new talent and capabilities in the organization to change millions of lives through our research."
About SKAN Research Trust
SKAN is a Bengaluru-based not-for-profit medical research trust that leverages transformational technologies to develop new therapies for ageing and neurological ailments, cardiovascular diseases, diabetes remission and lifestyle related disorders. SKAN applies its expertise in gut microbiome, genomics, stem cells, molecular biology, biomarkers, immunotherapies, nutrition, and alternate therapies to uncover kinder and gentler treatment protocols for ailments. Bioinformatics at SKAN vigorously pursues cutting-edge artificial intelligence, machine learning and other advanced technologies to predict, pre-empt, diagnose, treat, and facilitate remission of medical disorders. The Mission statement of SKAN is "Transform the future of medicine. Impacting millions of lives".
Media contact: [email protected]
Careers: [email protected]
Logo: https://mma.prnewswire.com/media/2082007/4257624/SKAN_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/dr-yogesh-shouche-is-appointed-as-director-of-skan-302222215.html
SOURCE SKAN Research Trust
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Skyven Arcturus Heat Pump Achieves COP of 8.0, Marking A New Level of Industrial Steam Efficiency
- Lasso Security Announces Future of AI Security with CPU-based Guardrails
- TORM plc capital increase in connection with exercise of Restricted Share Units as part of TORM's incentive program
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share